DOCSLIB.ORG

Research Report 2004 from the President & Ceo

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Research Report 2004 from the President & Ceo Toronto General Hospital Toronto Western Hospital Princess Margaret 20 Hospital 04 RESEARCH REPORT ABOUT RESEARCH ABOUT RESEARCH AT UNIVERSITY HEALTH NETWORK 20 Total Number of Researchers 468 Senior Scientists 160 Scientists 54 Affiliate Scientists 47 04 CSRC Members 207 Contents Investing in Future Health - From the President & CEO 1 Total Number of Trainees 770 Strong Funding Based on Strong Science - From the VP 2 Fellows 397 The Year in Review 4 Ontario Cancer Institute 6 PhD Students 81 Toronto General Research Institute 8 Toronto Western Research Institute 10 Other Graduate Students 292 Features 12 Breakthroughs 18 Staff 996 Funding 30 Committees/Services 32 Research Space 480,000 sq ft Analysis of Research Activity 35 Publications 1293 Endowed Chairs 36 International Research Advisory Board 37 Total Research Funding $155,976,000 RESEARCH REPORT 2004 FROM THE PRESIDENT & CEO Investing in Future Health Tom Closson niversity Health Network in 2004 is an amazing commitment of our researchers and research staff and their place to be, and UHN Research is one of the things partners in the government, community and private sector. U that makes it so. From the research funding flowing from federal, provincial Patient care, education, and research are all highly intercon- and international agencies, to the community volunteers who nected. UHN attracts some of the best clinicians—because it sit on our boards and committees, to the enormously dedicated offers the opportunity to combine clinical practice with research. work of the three UHN Foundations—the Arthritis & UHN attracts many patients from across Ontario due to high Autoimmunity Research Centre Foundation, the Princess standards of care and the opportunity to participate in ground- Margaret Hospital Foundation and the Toronto General & breaking clinical research—all because of the thriving Western Hospital Foundation—we owe an enormous debt research community here. of thanks to many groups for their ongoing support. The UHN strategic plan, Strategic Directions 2011, outlines An investment in biomedical research is an investment ambitious targets for all of us at UHN. As this Research Report in future health. UHN has much to be proud of in this area. documents, Research is making great strides towards these Please read on to learn more. targets. This year saw new buildings, new institutes, new Tom Closson initiatives and new partnership ventures in Research. President and Chief Executive Officer None of this would be possible without the hard work and University Health Network UNIVERSITY HEALTH NETWORK 1 FROM THE VICE PRESIDENT Strong Funding Based on Strong Science Christopher J. Paige, PhD esearch has had an amazing year in 2003/04. impressive. As a hospital-based This year for the first time our research budget This year for the research institute, our programs R topped $150M, with strong support from provincial first time our of inquiry span the spectrum from and national agencies including an all-time high of $20.5M from research budget fundamental understanding of the national Canadian Institutes of Health Research, nearly topped $150M molecules and cells to mission- $10M from the National Cancer Institute of Canada and $6M oriented, disease-specific clinical from the new Ontario Cancer Research Network. These figures research. Our discoveries reflect this diversity: the first approved demonstrate yet again the scientific excellence of our scientists treatment for SARS; a multi-drug protocol that extends the lives and the members of their research programs. They also show of lung cancer patients; identification of a leukemia stem cell; how reliant we are on a strong research funding environment discovery of a new mechanism that controls brain cell death to fuel research at UHN and how this support is key in realizing during stroke; and a novel molecular switch that controls the the research achievements that generate advances in patient process of inflammation. Breakthroughs like these hold the care at Canada’s largest hospital. promise of improving the lives of our patients today or in the Topping off the year came the announcement in March that not too distant future. our researchers won $36.4M in infrastructure funding from federal UHN’s achievements rest on the achievements of our and provincial sources to launch three new centres—the Advanced individual investigators. UHN researchers have received Medical Discovery Institute, the Centre for Research in Immune many individual honours this year, achieving global Tolerance in Transplantation, and the STTARR Centre in radia- and national renown. Some of these include: tion medicine. We are tremendously proud of this achievement ■ The Paul Ehrlich and Ludwig Darmstaedter Prize, the highest and it will prove critical in developing our research capacity in prize awarded in Germany in the field of medicine, awarded key areas in the next few years. to Dr. Tak Mak In 2003/04 UHN’s list of scientific accomplishments was ■ The appointments of Dr. Peter St George-Hyslop as Fellow 2 RESEARCH REPORT 2004 FROM THE VICE PRESIDENT of the Royal Society and Dr. John Dick as a Fellow UHN’s strengths in basic, transla- of the Royal Society of Canada UHN Global tional and clinical research to accel- ■ The naming of Drs. Jim Woodgett and Peter St George- Ventures is a new erate innovations further down the Hyslop as International Research Scholars by the R&D interface that development pipeline and capture Howard Hughes Medical Institute will capitalize on more value for UHN’s research ■ The appointments of Drs. Cheryl Arrowsmith, Dan Drucker UHN’s strengths investment. A third new venture and Mitsu Ikura as Tier I Canada Research Chairs and owes a great deal to the Princess Dr. Peter Cheung as a Tier II Canada Research Chair Margaret Hospital Foundation, which was a driving force ■ The Society for Thoracic Surgeons’ Earl Bakken award for behind its development. The Institute for Breast Cancer lifetime scientific achievement, awarded to Dr. Richard Weisel Research, opened this year under the leadership of Dr. Tak ■ Honorary degrees from the University of Toronto awarded Mak, is an exciting development in the field and will no doubt to Drs. Jim Till and Ernest McCulloch, who were also this be the focus of many future pieces in this report. year elected to the Canadian Medical Hall of Fame All told, the year 2003/04 was an important year in the growth ■ Dr. Tony Lang, who received the American Academy of UHN’s research enterprise. And, as in previous years, I’d like of Neurology’s Movement Disorders Research Award to close by offering my thanks and congratulations to all who Finally, this year saw progress in three significant new contributed to UHN Research’s success in 2003/04: our scien- ventures. The Toronto Medical Discovery Tower, critical for tists and clinician-scientists, our technical and support staff, our increasing research space capacity, neared completion this students and fellows, our colleagues in the Toronto Academic year and we are currently awaiting handover of the shell Health Sciences Network, and, most especially, our Foundations. space for UHN’s interior fit-out and occupancy in 2005. UHN Christopher J. Paige, PhD Global Ventures was launched this year under the leadership Vice President, Research of Dr. Brian Barber. This R&D interface will capitalize on University Health Network UNIVERSITY HEALTH NETWORK 3 HIGHLIGHTS The Year in Review DECEMBER 2003 The second meeting of the UHN International Research Advisory Board brings together four internationally-recognized scientists in high-impact areas to meet with various UHN constituencies including researchers, platform leaders, medical program leaders, foundations and hospital and research leadership. JANUARY 2004 The UHN Platform planning process, Phase II of The Future Project, launches. Led by Platform Chairs, the nine-month process aims NOVEMBER 2003 to define visions and new The second annual UHN tactical plans for the four Research Day held at UHN Platforms: Genes, a Toronto hotel provides Proteins & People, Health a chance for researchers Informatics, Medical to mingle and learn about Technology Innovation, and projects and findings from Regenerative Medicine. UHN colleagues. Keynote speaker was Dr. Catherine MARCH 2004 Verfaille, Director of the Stem Cell Institute at the The Research strategic plan University of Minnesota. entitled The Future Project is Also announced at the event approved by the UHN Board was the recipient of the of Trustees. inaugural UHN Inventor of the Year award: Dr. Kevin Three teams of UHN Kain, honoured for his work researchers celebrate the in new malaria treatments. announcement of awards totaling nearly $18.2M from the Canada Foundation 4 RESEARCH REPORT 2004 HIGHLIGHTS for Innovation to build new infrastructure to study the mechanisms of cancer, radia- tion medicine and immune tolerance. These awards were later matched by the Ontario government (Ministry of Economic Development and Trade/Ontario Innovation Trust), bringing funding to a total of $36.4M. APRIL 2004 Dr. Peter St George-Hyslop becomes Director of the Toronto Western Research Institute. His research in determining the genetic and molecular processes underlying neurodegenerative diseases, particularly Alzheimer’s disease, has had a major impact in the field and has been recognized by many national and interna- tional awards. MAY 2004 JUNE 2004 ▲ Dr. Brian Barber is recruited A significant milestone is to helm UHN Global Ventures, reached as the new Toronto Integrating basic, translational a new initative promoting com- Medical Discovery Tower is and clinical research, the mercialization and partnership topped off in a short ceremony new $125M Institute for Breast with UHN Research on an held 15 floors above ground. Cancer Research launches international level. UHN is eagerly anticipating the on June 2, 2004. Director hand-over of the building for Dr. Tak Mak begins assembling fit-out starting October 2004. Canada’s first scientific team to develop new improved drugs and therapies to conquer breast cancer.
Load more

Recommended publications
  • Canada Scientific Advisory Committee (CSAC)
    Canada Scientific Advisory Committee (CSAC) Alan Bernstein, PhD – Co-chairperson Canadian Institute for Advanced Research Toronto, Ontario Alan Bernstein is President of the Canadian Institute for Advanced Research (CIFAR), Canada’s global research institute. From 2008- 2011, Bernstein was the executive director of the Global HIV Vaccine Enterprise, an international alliance of researchers and funders charged with accelerating the search for an HIV vaccine. Previously, he served as the founding president of the Canadian Institutes of Health Research (2000-2007), Canada’s federal agency for the support of health research. In that capacity, he led the transformation of health research in Canada. After receiving his PhD from the University of Toronto, and following postdoctoral work in London, Bernstein joined the Ontario Cancer Institute (1974-1985). In 1985, he joined the new Samuel Lunenfeld Research Institute in Toronto, was named Associate Director in 1988 and then Director of Research (1994-2000). Internationally known for his contributions to our understanding of the molecular basis of cancer, Bernstein has made extensive contributions to the study of stem cells, hematopoiesis and cancer. He chairs or is a member of advisory and review boards in Canada, the US, UK and Italy. Bernstein has received numerous awards and honourary degrees for his contributions to science, including the 2008 Gairdner Wightman Award, induction into the Canadian Medical Hall of Fame, and the Henry G. Friesen International Prize in Health Research. He is a Senior Research Fellow of Massey College, received the Order of Ontario in 2018 and was appointed an Officer of the Order of Canada in 2002.
    [Show full text]
  • ANNUAL REPORT 2015/2016 Message from the Minister of Research, Innovation and Science
    ANNUAL REPORT 2015/2016 Message from the Minister of Research, Innovation and Science On behalf of the Government of Ontario I am pleased to have the opportunity to extend my thanks to the Ontario Institute for Cancer Research (OICR) for another successful year in its progress to meet the cancer challenge. A report issued recently by Cancer Care Ontario tells us that one in two Ontarians will develop cancer in their lifetime and cancer is the leading cause of death in the province. We have to do everything possible to alleviate the burden of cancer on Ontario families by improving the prevention, detection, diagnosis and treatment of cancer. We are proud of our investment in OICR over the last 10 years and recently approved the Institute’s Strategic Plan for 2016-2021. OICR has demonstrated leadership in the cancer community not only in its research programs but also in its focus on moving discoveries into the clinic. An example is the development of a novel oncolytic viral immunotherapy which is now in clinical trials. Through OICR’s commercialization partner, the Fight Against Cancer Innovation Trust, financial and in-kind support are attracted which makes it possible to accelerate development and therefore bring new hope to patients. The past year has been one of accomplishment and one of transition. Dr. Calvin Stiller, who was instrumental in the creation of the Institute, has stepped down as Chair of the Board of Directors. We are most grateful for his vision and leadership. Dr. Tom Hudson, who built the Institute, attracted talented researchers and launched provincial, national and international initiatives that are helping to make Ontario a world leader in cancer research, has moved on to the next phase of his career.
    [Show full text]
  • Princess Margaret Cancer Centre Annual Report
    2 015 A NNU A L REPORT 3 Leadership Message 4 Our Program 4 Who we are Welcome to the 2015 Annual Report for the Princess Margaret Cancer Centre at the University Health Network (UHN). This year proved to be both exciting and engaging as we continue to deliver revolutionary cancer care for our patients, and we are looking 6 Clinical Care forward to sharing the progress we have made. The 2015 edition showcases the recent 6 Our Clinical Programs LEADERSHIP activities and accomplishments of our people, departments, disease groups, and research and education programs. As one of the largest comprehensive cancer treatment facilities in the world, we have a great deal to share as we continue our efforts to be on the 8 Personalized Cancer Medicine MESSAGE frontiers of medical, surgical and radiation oncology, embracing the latest technology 8 Our Strategy and international best-practices, and setting standards for patient care. 9 We Are Transforming Patient Care In 2015, we celebrated 20 years of our presence on University Avenue; the hub of the discovery district. The move not only signified our commitment to meet the increased 11 We Are Augmenting Correlative Cancer Biology demands and evolving needs of our patients, but also encouraged collaboration, innovation, and research, enabling us to continue making progress in conquering cancer. 12 We Are Accelerating Guided Therapeutics Today, we again embrace change as we drive implementation of our space plan, with Marnie Escaf MHA, HBBA 15 We Are Expanding Novel Therapeutics Senior Vice President a focus on redeveloping facilities to improve the patient experience, including patient Executive Lead amenities, access, flow, and wayfinding.
    [Show full text]
  • Annual Report JULY 1, 2012 – JUNE 30, 2013
    Department of Surgery Annual Report JULY 1, 2012 – JUNE 30, 2013 Department of Surgery Annual Report JULY 1, 2012 – JUNE 30, 2013 R.S. Mclaughlin Professor And Chair Dr. J.T. Rutka Associate Chair And Vice-Chairs Dr. O. Rotstein Associate Chair Dr. D.A. Latter Vice-Chair, Education Dr. R.R. Richards Vice-Chair, Clinical Dr. B. Alman Vice-Chair, Research/A.J. Latner Professor and Chair of Orthopaedics Dr. R. McLeod Vice-Chair, Quality Dr. A. Kapus Associate Chair, Research Surgeons In Chief Dr. J.G. Wright The Hospital for Sick Children/Robert B. Salter Chair in Surgical Research Dr. J.S. Wunder Mount Sinai Hospital/Rubinoff-Gross Chair in Orthopaedics Dr. C. Compeau St. Joseph’s Health Centre Dr. O.D. Rotstein St. Michael’s Hospital Dr. A. Nathens Sunnybrook Health Sciences Centre Dr. G. Simone The Toronto East General Hospital Dr. S. Keshavjee University Health Network/James Wallace McCutcheon Chair in Surgery Dr. J.L. Semple Women’s College Hospital University Division Chairs Dr. C. Morshead Anatomy Dr. C. Caldarone Cardiac Surgery Dr. A. Smith General Surgery/Bernard and Ryna Langer Chair Dr. A. Lozano Leslie Dan Professor and Chair of Neurosurgery Dr. B. Alman A.J. Latner Professor and Chair of Orthopaedics Dr. C. Forrest Plastic Surgery (Interim Chair) Dr. T. Waddell F.G. Pearson/R.J. Ginsberg Chair in Thoracic Surgery Dr. N. Fleshner Martin Barkin Chair in Urological Research Dr. T. Lindsay Vascular Surgery Table of Contents 39th Gallie Day 3 St Michael’s Hospital 89 Chair’s Report 7 Division of Cardiac Surgery 90 Research Report
    [Show full text]
  • (DMOH) Toronto General Hospital, University Health Network
    General & Consultative Academic Hematologist, Division of Medical Oncology and Hematology (DMOH) Toronto General Hospital, University Health Network The Department of Medicine, Faculty of Medicine at the University of Toronto and the Division of Medical Oncology and Hematology at the University Health Network (UHN) are seeking to recruit a general academic hematologist for the Toronto General Hospital’s Blood Disorders Program. The successful candidate will have an academic position of Clinician Investigator and must be eligible for a full-time clinical academic appointment at the rank of Lecturer or Assistant Professor at the University of Toronto. Effective start date is September 1, 2017, or shortly thereafter. The position is well suited to early career physicians with an interest in non- and pre-malignant hematology. Strong collaborative skills are required as there is an opportunity to form closer links with the malignant hematology clinics and with our principal referring internal stakeholders. The role will be primarily ambulatory clinic based, serving hematological complications from UHN’s Cardiac, Multi-Organ Transplant and Internal Medicine programs, as well as the local community. The candidate should have a strong academic interest in postgraduate MD teaching or in quality improvement/patient safety and uphold standards of excellence. Additional qualifications in these domains are preferred. The Blood Disorders Program is a core program within the Division of Medical Oncology & Hematology at the University Health Network. As one of the top health networks in the world, the University Health Network encompasses both the Princess Margaret Cancer Centre as well as the Toronto General Hospital along with each of their respective world-class research institutes: The Ontario Cancer Institute and Toronto General Research Institute.
    [Show full text]
  • Scientific Advisory Committee on Oncology Therapies (SAC-OT)
    Scientific Advisory Committee on Oncology Therapies (SAC-OT) Membership List Core Members Alexander H.G. Paterson, MD, FRCP, FACP, MBChB (Chair) Medical Oncologist, Department of Medical Oncology, Tom Baker Cancer Centre Professor, Department of Medicine and Oncology, University of Calgary Calgary, Alberta Biography: Alexander Paterson graduated Medicine from Edinburgh University, United Kingdom in 1977 and subsequently trained at St. Bartholomew’s Hospital and Royal Marsden, London, England. He is a Fellow of the Royal College of Physicians and has been a Medical Oncologist at the Tom Baker Cancer Centre in Calgary since 1990. He is also Professor in the Departments of Medicine and Oncology at the University of Calgary, Alberta since 1995. He is a member of the Alberta Out-of-Province/Country Health Services Appeal Panel and the Board of Directors of the National Surgical Adjuvant Breast and Bowel Project (NSAPB). He is also Chair of the NSABP Protocol B-34 and the Alberta Breast Cancer Programme. He has published over 100 articles, authored over 15 book chapters, is the Editor of Fundamental Problems in Breast Cancer (I and II) and contributes a regular column to Alberta Doctors’ Digest. He has given over 200 invited lectures. Rick Abbott, BScPharm, RPEBC Pharmacy Manager, Provincial Systemic Therapy, Dr. H. Bliss Murphy Cancer Centre, Eastern Health St. John’s, Newfoundland and Labrador Biography: Rick Abbott graduated from the School of Pharmacy in 1990 at the Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador. He has been the Pharmacy Manager of the Provincial Systemic Therapy since 2002 and is actively involved in the Pharmacy Profession.
    [Show full text]
  • By the Numbers Excellence, Innovation, Leadership: Research at the University of Toronto a Powerful Partnership
    BY THE NUMBERS EXCELLENCE, INNOVATION, LEADERSHIP: RESEARCH AT THE UNIVERSITY OF TORONTO A POWERFUL PARTNERSHIP The combination of U of T and the 10 partner hospitals affiliated with the university creates one of the world’s largest and most innovative health research forces. More than 1,900 researchers and over 4,000 graduate students and postdoctoral fellows pursue the next vital steps in every area of health research imaginable. UNIVERSITY OF TORONTO Sunnybrook Health St. Michaelʼs Sciences Centre Hospital Womenʼs College Bloorview Kids Hospital Rehab A POWERFUL PARTNERSHIP Baycrest Mount Sinai Hospital The Hospital University Health for Sick Children Network* Centre for Toronto Addiction and Rehabilitation Mental Health Institute *Composed of Toronto General, Toronto Western and Princess Margaret Hospitals 1 UNIVERSITY OF TORONTO FACULTY EXCELLENCE U of T researchers consistently win more prestigious awards than any other Canadian university. See the end of this booklet for a detailed list of awards and honours received by our faculty in the last three years. Faculty Honours (1980-2009) University of Toronto compared to awards held at other Canadian universities International American Academy of Arts & Sciences* Gairdner International Award Guggenheim Fellows National Academies** Royal Society Fellows Sloan Research Fellows American Association for the Advancement of Science* ISI Highly-Cited Researchers*** 0 20 40 60 801 00 Percentage National Steacie Prize Molson Prize Federal Granting Councilsʼ Highest Awards**** Killam Prize Steacie
    [Show full text]
  • Printable List of Laureates
    Laureates of the Canadian Medical Hall of Fame A E Maude Abbott MD* (1994) Connie J. Eaves PhD (2019) Albert Aguayo MD(2011) John Evans MD* (2000) Oswald Avery MD (2004) F B Ray Farquharson MD* (1998) Elizabeth Bagshaw MD* (2007) Hon. Sylvia Fedoruk MA* (2009) Sir Frederick Banting MD* (1994) William Feindel MD PhD* (2003) Henry Barnett MD* (1995) B. Brett Finlay PhD (2018) Murray Barr MD* (1998) C. Miller Fisher MD* (1998) Charles Beer PhD* (1997) James FitzGerald MD PhD* (2004) Bernard Belleau PhD* (2000) Claude Fortier MD* (1998) Philip B. Berger MD (2018) Terry Fox* (2012) Michel G. Bergeron MD (2017) Armand Frappier MD* (2012) Alan Bernstein PhD (2015) Clarke Fraser MD PhD* (2012) Charles H. Best MD PhD* (1994) Henry Friesen MD (2001) Norman Bethune MD* (1998) John Bienenstock MD (2011) G Wilfred G. Bigelow MD* (1997) William Gallie MD* (2001) Michael Bliss PhD* (2016) Jacques Genest MD* (1994) Roberta Bondar MD PhD (1998) Gustave Gingras MD* (1998) John Bradley MD* (2001) Phil Gold MD PhD (2010) Henri Breault MD* (1997) Richard G. Goldbloom MD (2017) G. Malcolm Brown PhD* (2000) Jean Gray MD (2020) John Symonds Lyon Browne MD PhD* (1994) Wilfred Grenfell MD* (1997) Alan Burton PhD* (2010) Gordon Guyatt MD (2016) C H G. Brock Chisholm MD (2019) Vladimir Hachinski MD (2018) Harvey Max Chochnov, MD PhD (2020) Antoine Hakim MD PhD (2013) Bruce Chown MD* (1995) Justice Emmett Hall* (2017) Michel Chrétien MD (2017) Judith G. Hall MD (2015) William A. Cochrane MD* (2010) Michael R. Hayden MD PhD (2017) May Cohen MD (2016) Donald O.
    [Show full text]
  • Annual Report 2010-2011
    ON TARIO IN STIT U T E FOR C A N C E R RE S Ontario Institute for E ARC H ANNU Cancer Research A L REP ANNUAL REPORT 2010/11 ORT 2010/11 MaRS Centre, South Tower 101 College Street Suite 800 Toronto, Ontario Canada M5G 0A3 Telephone 416.977.7599 Toll-free 1.866.678.6427 [email protected] www.oicr.on.ca Funding for the Ontario Institute for Cancer Research is provided by the Government of Ontario. CJ23389 Cover.indd 1 11-07-07 6:56 PM Message from the Minister of Research and Innovation It is my pleasure to thank the Ontario Institute for Cancer Research (OICR) for the outstanding work it has done over For information about the the past year to improve the health and wellbeing of the people of Ontario. Ontario Institute for Cancer Research please contact: T he work you do has a direct impact on the lives of everyone in the province. It offers hope to the nearly 70,000 Ontarians Rhea Cohen who will be diagnosed with cancer in 2011 and to many millions more around the world. T he survival rate for most types Director of Communications [email protected] of cancer is constantly improving – and your work is helping to make that happen. 416-673-6642 OICR is recognized around the world for its leadership in cancer research. T he Institute’s high profile role – and that of its President and Scientific Director, Dr. Tom Hudson – in the International Cancer Genome Consortium is just one example of that leadership.
    [Show full text]
  • From Pro Athletes to Physicians
    SPRING 2015 UNIVERSITY OF TORONTO MEDICAL ALUMNI ASSOCIATION MAGAZINE MAAMATTERS TEAM PLAYERS From pro athletes to physicians Thanks To donors • dr. Peggy hill lecTureshiP TO COME TREASURER’S REPORT Dr. LynDon MaScarenhaS (1984) Increased donor support helps to fund important initiatives DONORS RESPONDED GENEROUSLY augment our support to the Medical conference; the Aboriginal Health Elective in 2013/2014, allowing us to help students Society with $ 25,850 in funds for both (funded by the MAA’s 4T6 Memorial Fund); with interest-free loans, as well as a number academic and non-academic initiatives. and a Daffydil alumni reception. We are of student-life initiatives. In November 2014 we inaugurated the pleased to announce that the MAA hosted its Thanks to your support, we received Dr. Marguerite (Peggy) Hill (5T2) Annual firstL eadership Circle fundraising event, with $335,000 in mail, online and miscellaneous Lectureship on Indigenous Health with a reception and luncheon in April this year. Pho donations, a 36 per cent increase from Dr. Evan Adams as the first guest lecturer; it As of Feb. 28, 2015, with the guidance T o G 2012/2013. We also received over $46,850 was a successful and inspiring event. We have of Mr. Dennis Babcock of BMO Nesbitt ra P in individual bequests and donations to maintained our commitment in 2014/15 Burns, our portfolio grew to $4,437,492, Jay hy: endowed funds, a decrease from the with funding to several student-organized an increase of 12 per cent from 2014. S on Ga previous year. We disbursed $90,000 in groups, conferences and events, including: Thanks to all donors for their support, LL student loans, over $130,000 in awards, the U of T International Health Program as well as our volunteer board and Ruth o scholarships and grants, and were able to (UTIHP) annual health and human rights Gillings, our administrator.
    [Show full text]
  • National C Ancer Institute Annual Report 2004
    Division of Extramural Activities Annual Report 2004 National Cancer Institute National Cancer U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Molecular Imaging for Cancer The NCI has made a significant committment to support the discovery, development, and delivery of cutting- edge molecular imaging agents and technologies. The field of molecular imaging has grown rapidly in response to this committment, and the applications being developed will have a far-reaching impact on the detection, diagnosis, and treatment of cancer patients. The images on the cover demonstrate the power of two different types of molecular imaging techniques applied to cancer detection. The image on the top is generated using positron emission tomography-computed tomog- raphy (PET-CT) fusion imaging (image reproduced with permission from David W. Townsend, Ph.D., Department of Radiology, University of Tennessee). Computed-tomography (CT) alone, a technique based on the use of x-rays, is capable of generating images with exquisite anatomical detail, but does not provide the clinician with physiologic information about lesions that are detected. Conversely, positron emission tomogra- phy (PET) alone, a technique based on the use of radiolabeled imaging agents, provides the clinician with func- tional information about whether a lesion is cancerous or not, but the resulting images do not contain the anatomic detail necessary to determine exact location within the body. In the image shown, the radiolabeled agent being used is 2-[18F]fluoro-2-deoxy-D-glucose ([18F] FDG), an agent that reports on the increased metabolism occuring in a cancer cell. In the past, these two types of images were acquired using two sepa- rate machines at two different times.
    [Show full text]
  • Martin-Lawrence-Friedland-Fonds.Pdf
    University of Toronto Archives and Record Management Services Finding Aids – Martin L. Friedland fonds Contains the following accessions: B1998-0006 (pp. 2-149) B2002-0022 (pp. 150-248) B2002-0023 (pp 249-280) B2008-0033 and B2014-0020 (pp. 281-352) To navigate to a particular accession, use the bookmarks in the PDF file University of Toronto Archives Martin L. Friedland Personal Records Finding Aid November 1998 Accession No. B1998–0006 Prepared by Martin L. Friedland With revisions by Harold Averill University of Toronto Archives Accession Number Provenance B1998-0006 Friedland, Martin L. Martin Lawrence Friedland – A biographical sketch Note: Reference should also be made to Friedland’s curriculum vitae and the address on his receiving the Molson Prize in 1995, both of which are appended to the end of the accompanying finding aid. Martin Friedland was born in Toronto in 1932. He was educated at the University of Toronto, in commerce and finance (BCom 1955) and law (LLB 1958), where he was the gold medallist in his graduating year. He continued his academic training at Cambridge University, from which he received his PhD in 1967. Dr. Friedland’s career has embraced several areas where he has utilized his knowledge of commerce and finance as well as of law. He has been a university professor and administrator, a shaper of public policy in Canada through his involvement with provincial and federal commissions, committees and task forces, and is an author of international standing. Dr. Friedland was called to the Ontario Bar in 1960. His contribution to the formation of public policy in Canada began with his earliest research, a study of gambling in Ontario (1961).
    [Show full text]